DAK-Gesundheit is procuring a non-exclusive rebate agreement for the active substance Guselkumab (100mg strength only), ATC L04AC16, for the period 1 December 2026 to 31 March 2027 in Hamburg, Germany. The estimated value is 1 EUR. The submission deadline is 5 February 2027. Notice, tender documents and submission instructions are available on oeffentlichevergabe.de.
Risk analysis is not yet available for this country's tenders. Currently supported: Estonia, Latvia, Lithuania, Poland, France, UK, Denmark, Netherlands, Norway, and Finland.
Get an AI-powered winning strategy tailored to this tender. Includes win probability score, key opportunities and challenges, recommended bid focus areas, competitive positioning insights, and actionable recommendations to maximize your chances.
LoginUpgrade to see which companies are likely to bid on this tender, based on historical procurement data.
LoginAI extracts and organizes all requirements from tender documents — mandatory qualifications, technical specifications, financial conditions, and submission rules — clearly categorized so you know exactly what's needed to bid.
Login1 documents available with AI summaries
Sign up to view document summaries and analysis
Comprehensive quality analysis of this tender scoring legal compliance, clarity, completeness, fairness, practicality, data consistency, and sustainability on a 0-100 scale with detailed breakdown and recommendations.
LoginHello! I'm your AI assistant for this tender. I can help you understand requirements, deadlines, eligibility criteria, and provide strategic insights.
No credit card required